Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 8.1% – Time to Buy?

Posted by George Bondi on Jun 4th, 2026

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) shot up 8.1% on Thursday . The stock traded as high as $16.92 and last traded at $17.2810. 161,415 shares were traded during mid-day trading, a decline of 91% from the average session volume of 1,897,089 shares. The stock had previously closed at $15.99.

Analyst Ratings Changes

Several research firms recently weighed in on ADPT. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. TD Cowen lifted their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. decreased their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Morgan Stanley decreased their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Finally, Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.57.

View Our Latest Stock Analysis on ADPT

Adaptive Biotechnologies Stock Performance

The stock has a market capitalization of $2.77 billion, a PE ratio of -52.33 and a beta of 2.15. The business has a 50 day moving average of $14.03 and a two-hundred day moving average of $15.57.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.20) EPS. On average, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 37,263 shares of the stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $15.19, for a total value of $566,024.97. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at approximately $33,122,068.42. This trade represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 19,037 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $14.23, for a total value of $270,896.51. Following the sale, the chief operating officer owned 377,802 shares in the company, valued at $5,376,122.46. The trade was a 4.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,771,096 shares of company stock worth $23,926,217. 5.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Large investors have recently modified their holdings of the business. Allianz Asset Management GmbH grew its stake in shares of Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after acquiring an additional 242,474 shares during the last quarter. UBS Group AG grew its stake in shares of Adaptive Biotechnologies by 101.6% during the fourth quarter. UBS Group AG now owns 511,927 shares of the company’s stock worth $8,314,000 after acquiring an additional 257,947 shares during the last quarter. Affinity Wealth Management LLC purchased a new stake in shares of Adaptive Biotechnologies during the third quarter worth about $4,541,000. Jupiter Asset Management Ltd. grew its stake in shares of Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after acquiring an additional 91,683 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Adaptive Biotechnologies by 103.9% during the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after acquiring an additional 1,363,181 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.